SRPT Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of 24.92%. Sarepta Therapeutics's return on equity of -20.94% beat Biomarin Pharmaceutical's return on equity of 9.62%.

Sarepta Therapeutics has a consensus price target of $89.96, signalling upside risk potential of 139.25%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $95.91 which suggests that it could grow by 65.16%. Given that Sarepta Therapeutics has higher upside potential than Biomarin Pharmaceutical, analysts believe Sarepta Therapeutics is more attractive than Biomarin Pharmaceutical.

Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $744.9M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.1M. Sarepta Therapeutics's net income of -$447.5M is lower than Biomarin Pharmaceutical's net income of $185.7M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Biomarin Pharmaceutical's PE ratio is 21.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.87x versus 3.89x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Edgewise Therapeutics has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of --. Sarepta Therapeutics's return on equity of -20.94% beat Edgewise Therapeutics's return on equity of --.

Sarepta Therapeutics has a consensus price target of $89.96, signalling upside risk potential of 139.25%. On the other hand Edgewise Therapeutics has an analysts' consensus of $39.00 which suggests that it could grow by 173.11%. Given that Edgewise Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Edgewise Therapeutics is more attractive than Sarepta Therapeutics.

Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $744.9M, which are larger than Edgewise Therapeutics quarterly revenues of --. Sarepta Therapeutics's net income of -$447.5M is lower than Edgewise Therapeutics's net income of -$40.8M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.87x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of -907.48%. Sarepta Therapeutics's return on equity of -20.94% beat Moderna's return on equity of -29.23%.

Sarepta Therapeutics has a consensus price target of $89.96, signalling upside risk potential of 139.25%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 79.58%. Given that Sarepta Therapeutics has higher upside potential than Moderna, analysts believe Sarepta Therapeutics is more attractive than Moderna.

Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $744.9M, which are larger than Moderna quarterly revenues of $107M. Sarepta Therapeutics's net income of -$447.5M is higher than Moderna's net income of -$971M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.87x versus 3.29x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of 23.33%. Sarepta Therapeutics's return on equity of -20.94% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Sarepta Therapeutics has a consensus price target of $89.96, signalling upside risk potential of 139.25%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.12 which suggests that it could grow by 13.14%. Given that Sarepta Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Vertex Pharmaceuticals.

Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.928%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $744.9M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Sarepta Therapeutics's net income of -$447.5M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.87x versus 10.31x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.